ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,457,000 | -46.2% | 2,100,000 | +3.1% | 0.36% | -43.0% |
| Q2 2023 | $43,570,400 | -46.5% | 2,036,000 | +1.2% | 0.63% | -46.2% |
| Q1 2023 | $81,365,280 | -15.8% | 2,012,000 | -3.2% | 1.17% | -30.5% |
| Q4 2022 | $96,668,560 | -10.1% | 2,078,000 | +0.3% | 1.69% | -9.5% |
| Q3 2022 | $107,475,000 | +9.8% | 2,072,000 | +0.1% | 1.86% | +9.2% |
| Q2 2022 | $97,849,000 | +22.3% | 2,070,000 | +84.2% | 1.71% | +10.3% |
| Q1 2022 | $80,006,000 | +1.3% | 1,124,000 | +6.4% | 1.55% | +19.7% |
| Q4 2021 | $78,968,000 | -24.3% | 1,056,000 | -42.5% | 1.29% | -26.9% |
| Q3 2021 | $104,303,000 | +18.5% | 1,836,000 | -8.2% | 1.77% | +12.1% |
| Q2 2021 | $88,020,000 | +8.3% | 2,000,000 | +21.4% | 1.58% | -15.5% |
| Q1 2021 | $81,279,000 | +42.4% | 1,648,000 | +21.5% | 1.87% | -3.9% |
| Q4 2020 | $57,088,000 | +138.0% | 1,356,000 | +158.8% | 1.94% | +123.2% |
| Q3 2020 | $23,989,000 | +47.5% | 524,000 | +61.7% | 0.87% | +21.8% |
| Q2 2020 | $16,268,000 | -44.3% | 324,000 | -43.0% | 0.71% | -60.5% |
| Q1 2020 | $29,212,000 | +20.0% | 568,000 | +44.2% | 1.81% | +28.6% |
| Q4 2019 | $24,335,000 | -30.2% | 393,895 | -32.1% | 1.40% | -39.2% |
| Q3 2019 | $34,846,000 | +8.7% | 580,000 | +52.6% | 2.31% | +14.3% |
| Q2 2019 | $32,064,000 | -9.8% | 380,000 | +2.2% | 2.02% | +3.9% |
| Q1 2019 | $35,533,000 | +0.3% | 372,000 | -25.6% | 1.94% | -27.5% |
| Q4 2018 | $35,415,000 | -9.1% | 500,000 | +9.6% | 2.68% | +14.7% |
| Q3 2018 | $38,970,000 | +171.2% | 456,000 | +267.7% | 2.34% | +149.4% |
| Q2 2018 | $14,372,000 | +34.6% | 124,000 | -6.1% | 0.94% | +14.8% |
| Q1 2018 | $10,680,000 | +106.8% | 132,000 | +50.0% | 0.82% | +58.6% |
| Q4 2017 | $5,164,000 | +2.2% | 88,000 | -18.5% | 0.52% | -13.4% |
| Q3 2017 | $5,054,000 | -46.8% | 108,000 | -59.1% | 0.60% | -50.9% |
| Q2 2017 | $9,499,000 | +13.4% | 264,000 | -2.9% | 1.21% | -30.0% |
| Q1 2017 | $8,378,000 | +9.7% | 272,000 | +19.3% | 1.73% | -4.3% |
| Q4 2016 | $7,638,000 | +35.4% | 228,000 | +7.5% | 1.81% | -0.2% |
| Q3 2016 | $5,641,000 | +6.6% | 212,000 | -11.7% | 1.81% | -10.2% |
| Q2 2016 | $5,292,000 | – | 240,000 | – | 2.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |